Resum
We report a novel series of non-peptide ligands that inhibit the growth factor receptor-bound protein 2 (Grb2)-Src homology 2 (SH2) domain binding, designed using a combined computational and NMR-driven approach. We have identified a new lead compound, 1n (IC50 = 56 μM), which is cytotoxic in HER2-positive breast cancer cells and disrupts the interaction between HER2 and Grb2. Thus, 1n can be used as a scaffold for the development of efficient Grb2-SH2 domain binding inhibitors. © 2011 American Chemical Society.
| Idioma original | Anglès |
|---|---|
| Pàgines (de-a) | 1096-1100 |
| Revista | Journal of Medicinal Chemistry |
| Volum | 54 |
| DOIs | |
| Estat de la publicació | Publicada - 24 de febr. 2011 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
-
ODG 3 – Bona salut i benestar
Fingerprint
Navegar pels temes de recerca de 'Development of non-peptide ligands of growth factor receptor-bound protein 2-src homology 2 domain using molecular modeling and NMR spectroscopy'. Junts formen un fingerprint únic.Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver